WO2001032157A3 - Pharmaceutical composition comprising a combination of metformin and glibenclamide - Google Patents

Pharmaceutical composition comprising a combination of metformin and glibenclamide Download PDF

Info

Publication number
WO2001032157A3
WO2001032157A3 PCT/US2000/028311 US0028311W WO0132157A3 WO 2001032157 A3 WO2001032157 A3 WO 2001032157A3 US 0028311 W US0028311 W US 0028311W WO 0132157 A3 WO0132157 A3 WO 0132157A3
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
combination
diabetes
glibenclamide
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/028311
Other languages
French (fr)
Other versions
WO2001032157A2 (en
Inventor
Beth Anne Piper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Priority to SK500-2002A priority Critical patent/SK287810B6/en
Priority to ROA200200560A priority patent/RO123109B1/en
Priority to BR0015294-3A priority patent/BR0015294A/en
Priority to NZ518278A priority patent/NZ518278A/en
Priority to AU10826/01A priority patent/AU780106B2/en
Priority to DE60038455T priority patent/DE60038455T2/en
Priority to EP00972122A priority patent/EP1229918B1/en
Priority to IL14913900A priority patent/IL149139A0/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to JP2001534362A priority patent/JP5183844B2/en
Priority to HU0300218A priority patent/HU229352B1/en
Priority to MXPA02004282A priority patent/MXPA02004282A/en
Priority to CA2389928A priority patent/CA2389928C/en
Priority to HK02107208.1A priority patent/HK1045655A1/en
Priority to EEP200200242A priority patent/EE05260B1/en
Priority to UA2002054481A priority patent/UA75583C2/en
Publication of WO2001032157A2 publication Critical patent/WO2001032157A2/en
Publication of WO2001032157A3 publication Critical patent/WO2001032157A3/en
Priority to IL149139A priority patent/IL149139A/en
Priority to NO20022087A priority patent/NO330026B1/en
Anticipated expiration legal-status Critical
Priority to BG106733A priority patent/BG65850B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method is provided for first line treatment of type 2 diabetes employing a combination of metformin and glyburide. A method for treating diabetes in drug naive human patients is also provided employing the above formulation to reduce insulin resistance and/or post-prandial glucose excursion and/or hemoglobin 1Ac, and/or increase post-prandial insulin, thereby treating the diabetes.
PCT/US2000/028311 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide Ceased WO2001032157A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
UA2002054481A UA75583C2 (en) 1999-11-03 2000-10-13 Method for treatment of diabetes
HU0300218A HU229352B1 (en) 1999-11-03 2000-10-13 Medicament comprising the combination of metformin and glyburide
BR0015294-3A BR0015294A (en) 1999-11-03 2000-10-13 Method for treating diabetes
NZ518278A NZ518278A (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide
AU10826/01A AU780106B2 (en) 1999-11-03 2000-10-13 Method for treating diabetes
DE60038455T DE60038455T2 (en) 1999-11-03 2000-10-13 MEDICAMENT, INCLUDING A COMBINATION OF METFORMIN AND GLIBENCLAMIDE
EP00972122A EP1229918B1 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide
CA2389928A CA2389928C (en) 1999-11-03 2000-10-13 Method for treating diabetes
ROA200200560A RO123109B1 (en) 1999-11-03 2000-10-13 Utilization of a composition based on metformin and glyburide for treating type 2 diabetes
JP2001534362A JP5183844B2 (en) 1999-11-03 2000-10-13 How to treat diabetes
MXPA02004282A MXPA02004282A (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide.
SK500-2002A SK287810B6 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide
IL14913900A IL149139A0 (en) 1999-11-03 2000-10-13 Pharmaceutical compositions containing metformin and glyburide
HK02107208.1A HK1045655A1 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide
EEP200200242A EE05260B1 (en) 1999-11-03 2000-10-13 Use of a low dose of metformin plus gluride combination for the treatment of first line type 2 sugar
IL149139A IL149139A (en) 1999-11-03 2002-04-15 Use of metformin and glyburide to prepare pharmaceutical compositions
NO20022087A NO330026B1 (en) 1999-11-03 2002-05-02 Use of metformin and glyburide for the preparation of a pharmaceutical composition
BG106733A BG65850B1 (en) 1999-11-03 2002-05-22 Use of a pharmaceutical composition containing a combination of metformin and glibenclamide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/432,465 1999-11-03
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes
US09/460,920 1999-12-14

Publications (2)

Publication Number Publication Date
WO2001032157A2 WO2001032157A2 (en) 2001-05-10
WO2001032157A3 true WO2001032157A3 (en) 2002-01-24

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/028311 Ceased WO2001032157A2 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide

Country Status (23)

Country Link
EP (1) EP1229918B1 (en)
JP (1) JP5183844B2 (en)
KR (1) KR20070089259A (en)
CN (1) CN1450902A (en)
AR (1) AR026356A1 (en)
AT (1) ATE390140T1 (en)
AU (1) AU780106B2 (en)
BR (1) BR0015294A (en)
CA (1) CA2389928C (en)
EE (1) EE05260B1 (en)
HU (1) HU229352B1 (en)
IL (1) IL149139A0 (en)
LT (1) LT5058B (en)
LV (1) LV12910B (en)
MX (1) MXPA02004282A (en)
NO (1) NO330026B1 (en)
NZ (1) NZ518278A (en)
PL (1) PL199278B1 (en)
RU (1) RU2275915C2 (en)
SK (1) SK287810B6 (en)
TW (1) TWI280125B (en)
UY (1) UY26424A1 (en)
WO (1) WO2001032157A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
FR2816840B1 (en) 2000-11-17 2004-04-09 Flamel Tech Sa MEDICINE BASED ON SUSTAINED RELEASE ANTI-HYPERCLYCEMIA MICROCAPSULES AND METHOD FOR PREPARING THE SAME
FR2825023B1 (en) * 2001-05-23 2005-04-15 Flamel Tech Sa ANTIDIABETIC ORAL PHARMACEUTICAL FORM "ONE TAKEN PER DAY" INCLUDING BIGUANIDE AND AT LEAST ONE OTHER ACTIVE INGREDIENT
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
MXPA04009968A (en) 2002-04-09 2004-12-13 Flamel Tech Sa Oral suspension of active principle microcapsules.
CA2544245A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
US7442720B2 (en) * 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
WO2005107730A2 (en) * 2004-05-03 2005-11-17 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
UA98799C2 (en) 2007-07-19 2012-06-25 Такеда Фармасьютикал Компани Лимитед Solid preparation comprising alogliptin and metformin hydrochloride
CN101801371B (en) 2007-09-10 2012-11-28 詹森药业有限公司 Process for the preparation of compounds useful as SGLT inhibitors
RU2372911C1 (en) * 2008-03-12 2009-11-20 Николай Евгеньевич Староверов Polymorphic analog therapy (versions)
PT3228320T (en) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combination of an insulin and a glp-1 agonist
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101337322B1 (en) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Pharmaceutical composition comprising a glp-1 agonist and methionine
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
LT2568988T (en) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt
ES2606554T3 (en) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
RU2572703C2 (en) * 2011-02-02 2016-01-20 Санофи-Авентис Дойчланд Гмбх Preventing hypoglycaemia in patients with type 2 diabetes mellitus
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (en) * 2019-10-31 2020-02-18 天津大学 Salt forming of sulfonylurea compound and metformin, preparation method and application
CN113143940A (en) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 Preparation method of antidiabetic pharmaceutical composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
US5922769A (en) * 1995-11-14 1999-07-13 Abiogen Pharma S.R.L. Glibenclamide-metformin combination for the treatment of diabetes mellitus of type II

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (en) * 1988-10-01 1991-09-12 Hoechst Ag METHOD FOR MICRONIZING GLIBENCLAMIDE
DK36392D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1787646A3 (en) 1997-06-18 2007-10-03 Smithkline Beecham Plc Novel method of treatment
DK0974356T3 (en) * 1998-07-15 2003-10-27 Merck Sante Sas Tablets comprising a combination of metformin and glibenclamide
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922769A (en) * 1995-11-14 1999-07-13 Abiogen Pharma S.R.L. Glibenclamide-metformin combination for the treatment of diabetes mellitus of type II
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D'ARGENZIO R ET AL: "[Comparison of two treatment models in type-II diabetic patients with poo metabolic control: Preformed combination of glibenclamide 2,5 mg + metformin 400 mg or mono-therapy with sulfonylurea at maximal doses? An evaluation at six months]. Confronto tra due modelli di trattamento in pazienti diabeti", MINERVA ENDOCRINOLOGICA, (1996 SEP) 21 (3) 101-10., XP001001165 *
HERMANN L.S. ET AL: "Antihyperglycaemic efficacy, response prediction and Dose-Response relations of treatment with metformin and sulphonylurea, alone and in primary combination.", DIABETIC MEDICINE, (1994) 11/10 (953-960), XP001001227 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides

Also Published As

Publication number Publication date
LT2002063A (en) 2003-06-25
HUP0300218A2 (en) 2003-06-28
JP2003519621A (en) 2003-06-24
AR026356A1 (en) 2003-02-05
AU780106B2 (en) 2005-03-03
IL149139A0 (en) 2002-11-10
HUP0300218A3 (en) 2006-02-28
PL364885A1 (en) 2004-12-27
PL199278B1 (en) 2008-09-30
RU2275915C2 (en) 2006-05-10
AU1082601A (en) 2001-05-14
NO20022087D0 (en) 2002-05-02
RU2002114820A (en) 2004-03-10
NO20022087L (en) 2002-06-24
CA2389928C (en) 2010-03-23
EP1229918B1 (en) 2008-03-26
WO2001032157A2 (en) 2001-05-10
LT5058B (en) 2003-09-25
CA2389928A1 (en) 2001-05-10
TWI280125B (en) 2007-05-01
HU229352B1 (en) 2013-11-28
EE200200242A (en) 2003-12-15
BR0015294A (en) 2003-07-15
SK5002002A3 (en) 2004-05-04
SK287810B6 (en) 2011-10-04
UY26424A1 (en) 2001-05-31
NZ518278A (en) 2004-10-29
NO330026B1 (en) 2011-02-07
LV12910B (en) 2003-05-20
EE05260B1 (en) 2010-02-15
ATE390140T1 (en) 2008-04-15
JP5183844B2 (en) 2013-04-17
CN1450902A (en) 2003-10-22
EP1229918A2 (en) 2002-08-14
MXPA02004282A (en) 2003-02-17
KR20070089259A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
HK1045655A1 (en) Pharmaceutical composition comprising a combination of metformin and glibenclamide
LT2002063A (en) Low-dose metformin and gliburide combinations for treating diabetes
Campbell et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus
IL87149A (en) 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
IT1291113B1 (en) NUTRITIONAL THERAPEUTIC COMPOSITION FOR SUBJECTS WITH DIABETES MELLITUS
CA2196174A1 (en) Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
NZ336755A (en) Use of gastrointestinal lipase inhibitors in particular tetrahydrolipstatin (orlistat)
MXPA02003495A (en) Pyridinium derivatives for the management of agingrelated and diabetic vascular complications, process for their preparation and therapeutic uses thereof.
CA2113856A1 (en) Antidiabetic Agent
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
Negrişanu et al. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy
RU96115219A (en) METHOD FOR TREATING PATIENTS WITH SUGAR DIABETES
AU6069794A (en) Method and compositions for noninvasive dose to effect administration of lipophilic drugs
Chlup et al. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 diabetes treated by means of an insulin pump
Noble Failure of cefotaxime in the treatment of Yersinia enterocolitica sepsis despite in vitro susceptibility.
JP2001316293A5 (en)
Nielsen et al. Prevalence of diabetes mellitus treated with insulin and oral hypoglycemic agents in Denmark
Aman et al. Clinical trial with glipizide in uncomplicated maturity onset diabetes mellitus
JP2022541322A5 (en)
Fujimoto Therapeutic utility of biguanides in the treatment of NIDDM
Lee Ask the doctor. I have diabetes and use insulin two, sometimes three, times a day to keep my sugar under control. My hope is that this will help me avoid a heart attack. Is this a reasonable goal?
Fetkovska et al. Long-term clinical experience with guanfacine
Rayfield Can strict glucose control prevent infections in diabetics?.
Jackson et al. A diabetic day in the outback
Walling Adolescent diabetes and use of insulin-like growth-factor-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 518278

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 5002002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 149139

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/03368

Country of ref document: ZA

Ref document number: 200203368

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/004282

Country of ref document: MX

Ref document number: 10826/01

Country of ref document: AU

Ref document number: IN/PCT/2002/00543/MU

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2002 200200560

Country of ref document: RO

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2001 534362

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027005673

Country of ref document: KR

Ref document number: PV2002-1546

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2389928

Country of ref document: CA

Ref document number: 2002/01222

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 106733

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2002063

Country of ref document: LT

WWE Wipo information: entry into national phase

Ref document number: 6466

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 2002 2002114820

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000972122

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008180326

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027005673

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000972122

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002063

Country of ref document: LT

WWP Wipo information: published in national office

Ref document number: PV2002-1546

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2002063

Country of ref document: LT

WWP Wipo information: published in national office

Ref document number: 518278

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 518278

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 10826/01

Country of ref document: AU